NOTVQ (Inotiv) Ending Cash Position: $15.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Inotiv Ending Cash Position?

Inotiv NOTVQ -26.00% Ending Cash Position is $15.2 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

Inotiv's Ending Cash Position for the quarter that ended in Mar. 2026 was $15.2 Mil.

Inotiv's quarterly Ending Cash Position declined from Sep. 2025 ($21.7 Mil) to Dec. 2025 ($12.7 Mil) but then increased from Dec. 2025 ($12.7 Mil) to Mar. 2026 ($15.2 Mil).

Inotiv's annual Ending Cash Position declined from Sep. 2023 ($35.5 Mil) to Sep. 2024 ($21.4 Mil) but then increased from Sep. 2024 ($21.4 Mil) to Sep. 2025 ($21.7 Mil).

Inotiv Ending Cash Position Related Terms

Inotiv Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Inotiv's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inotiv Ending Cash Position Chart

Inotiv Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 156.92 18.98 35.49 21.43 21.74

Inotiv Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.30 6.22 21.74 12.73 15.18

Inotiv Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Inotiv's Ending Cash Position for the fiscal year that ended in Sep. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=21.432+0.309
=21.7

Inotiv's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=12.732+2.448
=15.2

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $15.2 Mil mean?
Inotiv (NOTVQ) has a Ending Cash Position of $15.2 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Inotiv and its competitors.
Is Inotiv's Ending Cash Position too high?
Inotiv's current Ending Cash Position is $15.2 Mil.
How does Inotiv's Ending Cash Position compare to NSTM and PRPH?
Inotiv's Ending Cash Position of $15.2 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Inotiv and its competitors. Inotiv's current Ending Cash Position is $15.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Based on GuruFocus' analysis, Inotiv (NOTVQ) is currently considered Possible Value Trap. The stock's GF Value™ is $1.58, compared to a current price of $0.01 — trading 99.3% below its estimated fair value. The current Ending Cash Position is $15.2 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Inotiv (NOTVQ), the current Ending Cash Position is $15.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inotiv Business Description

Other Exchanges BS50:Germany
Address 2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.